News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

ThalassaX Therapeutics doses first patient in U.S. Phase I trial of CS231295

Saturday, July 18, 2026

ThalassaX Therapeutics United States Ltd has announced that the first patient has been dosed in its US Phase I clinical trial of CS a brainpenetrant Aurora B kinase selective inhibitor developed

European Commission approves JASCAYD® for IPF and PPF treatment in the EU

Saturday, July 18, 2026

The European Commission EC has granted marketing authorisation for JASCAYD nerandomilast for the treatment of adults with idiopathic pulmonary fibrosis IPF and progressive pulmonary fibrosis PPF Boehringer Ingelheim announced

Umoja Biopharma Receives FDA Clearance to Begin Clinical Trial of UB-VV400 In Vivo CAR T Cell Therapy

Friday, July 17, 2026

Umoja Biopharma has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UBVV a CDdirected in vivo CAR T cell therapy for adults

Boehringer Ingelheim Advances Obesity Pipeline with Phase II Trial of Triple Receptor Agonist

Friday, July 17, 2026

Boehringer Ingelheim has started a Phase II clinical trial of BI an investigational triple GLPGIPNPY receptor agonist for the treatment of people with obesity and overweight

Kairos Pharma Reports Positive Interim Safety Results from Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer

Thursday, July 16, 2026

Kairos Pharma has reported positive interim safety results from its ongoing Phase clinical trial of ENV carotuximab in combination with osimertinib Tagrisso for patients with advanced EGFRmutated nonsmall cell lung cancer NSCLC

Sinopia Biosciences Publishes Preclinical Study Supporting SB-0110 for Parkinson's Disease

Thursday, July 16, 2026

Sinopia Biosciences has published preclinical research in Science Translational Medicine highlighting a new approach to treating Parkinsons disease The study supports the development of SB

FDA Grants Fast Track Designation to SOTIO’s SOT109 for Advanced Colorectal Cancer

Wednesday, July 15, 2026

SOTIO Biotech has received Fast Track Designation FTD from the US Food and Drug Administration FDA for SOT its investigational antibodydrug conjugate ADC for the treatment of patients

FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Primary Membranous Nephropathy

Wednesday, July 15, 2026

Roche has announced that the US Food and Drug Administration FDA has granted Priority Review to its supplemental Biologics License Application sBLA for GazyvaGazyvaro obinutuzumab as a treatment

DA Approves LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease Treatment

Tuesday, July 14, 2026

Eisai and Biogen have received approval from the US Food and Drug Administration FDA for a supplemental Biologics License Application sBLA for LEQEMBI IQLIK lecanemabirmb a onceweekly subcutaneous injection for the initiation treatment of early Alzhe...

Armata Pharmaceuticals Secures FDA Agreement on Initial Paediatric Study Plan for AP-SA02

Tuesday, July 14, 2026

Armata Pharmaceuticals has received agreement from the US Food and Drug Administration FDA on its Initial Paediatric Study Plan iPSP for APSA supporting the future evaluation of the investigational